Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in
combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.
Phase:
Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborators:
Genentech, Inc. M.D. Anderson Cancer Center Massachusetts General Hospital